SCHEMBL19813050

SCHEMBL19813050

CNC(=O)OCC(OC)OC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CYP2D6 P10635 1/20 0.42
CHRM1 P11229 1/20 0.42
NFKB1 P19838 1/20 0.42
CHRM3 P20309 1/20 0.42
MAPK1 P28482 1/20 0.42
CHRNA7 P36544 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
LMNA P02545 1/20 0.41
APEX1 P27695 1/20 0.41
EPHX1 P07099 1/20 0.41
CYP1A2 P05177 1/20 0.38
KDM4E B2RXH2 1/20 0.31
APOBEC3A P31941 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12315113 0.82 CHRNB2 (0.42) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL15249606 0.78 CHRNB2 (0.46) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL9885917 0.77 CHRNB2 (0.42) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL18650145 0.76 CHRNB2 (0.48) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL6276297 0.76 MGAM (0.46) SMN1; SMN2
SCHEMBL13347915 0.76 CHRNB2 (0.45) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL967608 0.76
SCHEMBL2349139 0.75 ALDH1A1 (0.41) NFKB1SMN1; SMN2LMNAAPEX1
SCHEMBL9975571 0.74
SCHEMBL21680765 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11958862-B2 Compounds and compositions and uses thereof SUMITOMO PHARMA AMERICA, INC. (US) 2024-04-16 US disclosed
US-10927124-B2 Compounds and compositions and uses thereof SUNOVION PHARMACEUTICALS INC. (US) 2021-02-23 US disclosed
US-20190308990-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUNOVION PHARMACEUTICALS INC. 2019-10-10 US disclosed
EP-3494119-A2 COMPOUNDS AND COMPOSITIONS AND USES THEREOF Sunovion Pharmaceuticals Inc. (US) 2019-06-12 EP disclosed
US-10196403-B2 Compounds and compositions and uses thereof SUNOVION PHARMACEUTICALS INC. (US) 2019-02-05 US disclosed
US-20180030064-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUMITOMO PHARMA AMERICA, INC. 2018-02-01 US disclosed
WO-2018023072-A2 COMPOUNDS AND COMPOSITIONS AND USES THEREOF SUNOVION PHARMACEUTICALS, INC. (US) 2018-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196403-B2 Compounds and compositions and uses thereof CHAT, ACHE, MAOB CHRNB2 139/4885CHRNA4 246/4885CHRM2 296/4885
US-10927124-B2 Compounds and compositions and uses thereof CHAT, ACHE, MAOB CHRNB2 139/4885CHRNA4 246/4885CHRM2 296/4885
US-11958862-B2 Compounds and compositions and uses thereof CHAT, ACHE, MAOB CHRNB2 139/4885CHRNA4 246/4885CHRM2 296/4885
US-20180030064-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF CHAT, ACHE, MAOB CHRNB2 139/4885CHRNA4 246/4885CHRM2 296/4885
US-20190308990-A1 COMPOUNDS AND COMPOSITIONS AND USES THEREOF CHAT, ACHE, MAOB CHRNB2 139/4885CHRNA4 246/4885CHRM2 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.